The global market for Gene Amplification Technologies is forecast to witness revenues spike by over 31.7% in the year 2020 and thereafter continue to grow to reach US$6.8 billion by the year 2027, trailing a post COVID-19 CAGR of 11.4% over the analysis period 2020 through 2027. Gene amplification typically uses Polymerase Chain Reaction (PCR) which remains the most commonly used and effective technology since it permits researchers to obtain lots of gene replicas quickly. Fueled by the introduction of novel PCR instruments for the detection of several critical diseases, Polymerase Chain Reaction (PCR) continues to dominate the gene amplification market. Polymerase chain reaction technology was introduced to the market in 1980s. The technology is used to detect the type and amount of virus or bacteria present in biological samples and also allows amplification of genetic material in large quantities.

In the midst of the ongoing pandemic, diagnostic and antibody tests hold a critical role in identifying people with COVID-19 infection to support isolation or quarantine measures. These tests are expected to help governments in rapidly identifying and isolating infected people and tracking contacts to manage the situation. Molecular diagnostic tests available on the market rely on RT-PCR technology to target specific genomic parts of the virus for accurate, reliable detection. PCR-based techniques are capable of detecting low quantities of viral RNA to deliver high sensitivity and allow timely diagnosis of the COVID-19 infection. Current growth in the gene amplification market is therefore being driven by qPCR technique, closely followed by RT-PCR (Reverse Transcription PCR), the two most widely used testing technologies for COVID-19 disease. A lion's share of the millions of COVID-19 tests performed worldwide is accounted for by PCR based tests. Polymerase Chain Reaction (PCR) remains the most commonly used & effective technology for gene amplification as the technology permits researchers to create lots of gene replicas very quickly. The technology allows amplification of genetic material in large quantities and is cost-effective & has a rapid turnover rate. 10 months into the pandemic & with infections continuing to spread, the focus on testing, testing & testing promises to raise revenue potential for the technology by a massive 31.7% in the year 2020. Regionally, North America represents the largest market for PCR and is expected to retain its dominance, with the US remaining the single largest market.

The market also stands to benefit from the growing popularity of molecular diagnostics for cancer screening and infectious disease testing such as hepatitis B and C, HIV, flu virus and human papilloma virus. According to the W.H.O, more than 10 million people are expected to die of cancer by the year 2026. The market for oncology-specific molecular diagnostics is dominated by breast cancer, which has a share of 15% in the overall test volumes. There are several commercialized molecular diagnostic products available for breast cancer. Fastest growth in future however is expected to be reported by colorectal cancer. Molecular diagnostic markets for prostate cancer and liver cancer are also anticipated to see major growth in the coming years due to increasing prevalence of these cancer types. People suffering from various infectious diseases, such as GI, STDs, and respiratory diseases are also increasing in numbers. These grave statistics, though alarming, represent growth drivers for the latest diagnostic techniques and devices, including molecular diagnostics based on gene amplification. PCR assays detect the presence of organisms such as Chlamydia, mycoplasmas, mycobacteria, Herpes viruses and enteroviruses from clinical specimens. Commercial PCR assays for the diagnosis of tuberculosis and C. trachomatis infection are routinely used in diagnostic laboratories. PCR assay also detects antimicrobial resistance and are used to identify the cause of infection.